Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.
BACKGROUND
About 5% of school children have a specific learning disorder, defined as unexpected failure to acquire adequate abilities in reading, writing or mathematics that is not a result of reduced intellectual ability, inadequate teaching or social deprivation. Of these events, 80% are reading disorders. Polyunsaturated fatty acids (PUFAs), in particular, omega-3 and omega-6 fatty acids, which normally are abundant in the brain and in the retina, are important for learning. Some children with specific learning disorders have been found to be deficient in these PUFAs, and it is argued that supplementation of PUFAs may help these children improve their learning abilities.


OBJECTIVE
1. To assess effects on learning outcomes of supplementation of polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.2. To determine whether adverse effects of supplementation of PUFAs are reported in these children.


METHODS
In November 2015, we searched CENTRAL, Ovid MEDLINE, Embase, PsycINFO, 10 other databases and two trials registers. We also searched the reference lists of relevant articles.


METHODS
Randomised controlled trials (RCTs) or quasi-RCTs comparing PUFAs with placebo or no treatment in children younger than 18 years with specific learning disabilities, as diagnosed in accordance with the fifth (or earlier) edition of theDiagnostic and Statistical Manual of Mental Disorders (DSM-5), or the 10th (or earlier) revision of the International Classification of Diseases (ICD-10) or equivalent criteria. We included children with coexisting developmental disorders such as attention deficit hyperactivity disorder (ADHD) or autism.


METHODS
Two review authors (MLT and KHT) independently screened the titles and abstracts of articles identified by the search and eliminated all studies that did not meet the inclusion criteria. We contacted study authors to ask for missing information and clarification, when needed. We used the GRADE approach to assess the quality of evidence.


RESULTS
Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria. One study was conducted in a school setting, the other at a specialised clinic. Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo. Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study. In addition, one of the studies was funded by industry and reported active company involvement in the study.None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests.Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children). Investigators reported no other adverse effects.Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes. We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome. No other secondary outcomes were reported.We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder. We identified one ongoing study and found three studies awaiting classification.


CONCLUSIONS
Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders. Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed.
Department of Paediatrics, Penang Medical College, 4 Jalan Sepoy Lines, Georgetown, Penang, Malaysia, 10450.
May Loong
ML
Tan
Jacqueline J
JJ
Ho
Keng Hwang
KH
Teh
J Learn Disabil. 2008 Sep-Oct;41(5):460-73
18768777
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):89-93
10970719
Eur J Pediatr. 2010 Feb;169(2):149-64
19672626
Mil Med. 2014 Nov;179(11 Suppl):134-7
25373097
Brain Res. 2008 Oct 27;1237:35-43
18789910
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007986
22786509
J Child Neurol. 2004 Oct;19(10):744-58
15559890
Dyslexia. 2009 Nov;15(4):304-27
19384920
J Lipid Res. 2001 Oct;42(10):1655-63
11590222
J Nutr. 2008 Jun;138(6):1165-71
18492851
Lancet. 2012 Jun 9;379(9832):2151-61
22579125
Br J Nutr. 2015 Nov 28;114(10):1623-37
26359192
Child Care Health Dev. 2009 Jan;35(1):112-9
18991979
Cogn Behav Neurol. 2004 Mar;17(1):18-31
15209222
J Learn Disabil. 1985 Dec;18(10):581-4
4086934
J Am Coll Nutr. 2016;35(3):271-83
26252073
Am Fam Physician. 2006 Dec 15;74(12):2079-84
17186715
Prostaglandins Leukot Essent Fatty Acids. 2004 Apr;70(4):383-90
15041031
J Learn Disabil. 2008 Nov-Dec;41(6):514-23
18625783
Pediatrics. 2011 Mar;127(3):e818-56
21357342
J Dev Behav Pediatr. 2011 Apr;32(3):250-63
21285895
J Child Health Care. 2011 Dec;15(4):299-311
21828168
Physiol Behav. 1996 Apr-May;59(4-5):915-20
8778886
Biomed Pharmacother. 2002 Oct;56(8):365-79
12442909
Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):133-6
19493663
JAMA. 2010 Oct 20;304(15):1675-83
20959577
J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1020-32
9256582
Pediatr Clin North Am. 2008 Dec;55(6):1259-68, vii
19041456
Neurobiol Aging. 2005 Dec;26 Suppl 1:98-102
16226347
Nutr Health. 2006;18(3):233-47
17180869
Percept Mot Skills. 1994 Feb;78(1):131-41
8177650
Br J Nutr. 2015 Apr 28;113(8):1280-91
25791747
Pediatrics. 2005 May;115(5):1360-6
15867048
Future Child. 1996 Spring;6(1):54-76
8689262
Cochrane Database Syst Rev. 2011 Nov 09;(11):CD007992
22071839
Eur Child Adolesc Psychiatry. 2004;13 Suppl 3:3-13
15692877
Int J Vitam Nutr Res. 2000 Mar;70(2):31-42
10804454
Trends Neurosci. 1997 Apr;20(4):147-52
9106353
Nat Neurosci. 2007 Feb;10(2):135
17259957
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):89-96
19523794
Am J Clin Nutr. 2000 Jan;71(1 Suppl):323S-6S
10617990
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):1-9
10970706
J Child Neurol. 2004 Oct;19(10):765-71
15559892
N Engl J Med. 1998 Jan 29;338(5):307-12
9445412
Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):125-32
19501496
J Atten Disord. 2009 Mar;12(5):394-401
18448859
Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S
16841856
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):109-16
10970722
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009398
23235675
Eur Neuropsychopharmacol. 2007 Jan 15;17(2):116-21
16997534
Am J Clin Nutr. 1991 Sep;54(3):438-63
1908631
J Med Food. 2007 Dec;10(4):662-6
18158838
PLoS One. 2012;7(9):e43909
22970149
Lancet. 2000 Apr 22;355(9213):1429-30
10791530
J Lipid Res. 1997 Oct;38(10):2012-22
9374124
Prostaglandins Leukot Essent Fatty Acids. 2013 Aug;89(2-3):71-9
23756346
Nutrition. 2012 Jun;28(6):670-7
22541055
Br J Psychiatry. 1995 May;166(5):654-9
7620753
J Learn Disabil. 2013 Jan-Feb;46(1):43-51
23144063
J Child Neurol. 2012 Jun;27(6):747-53
22596014
Am J Cardiol. 2007 Mar 19;99(6A):35C-43C
17368277
Lancet. 2006 May 27;367(9524):1747-57
16731270
Res Dev Disabil. 2010 May-Jun;31(3):731-42
20172688
JAMA. 2014 Aug 27;312(8):839-40
25157728
J Atten Disord. 2015 Nov;19(11):954-64
24214970
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):233-9
11817499
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):69-74
10970716
Prostaglandins Leukot Essent Fatty Acids. 2011 Nov;85(5):253-60
21596549